Printer Friendly

Sindrome de lesion por reperfusion miocardica.

Titulo: Myocardial Ischaemia-Reperfusion Syndrome


Cardiovascular diseases occupy the first place in worldwide mortality. Much of this proportion is due to heart disease caused by ischaemia, which is usually caused by the obstruction of a coronary artery secondary to the rupture of an atherosclerotic plaque. Prolonged ischaemia can lead to irreversible myocardial damage and cell death, and it has been demonstrated that if the ischaemia is quickly reversed, myocardial tissue recovery occurs. Therapeutic efforts are aimed to achieve the restoration of blood flow to ischaemic myocardial tissue for this reason, a strategy that has been termed 'reperfusion' and is thought to stop the main mechanism of cell damage, i.e. hypoxia. However, there is a phenomenon in which despite having achieved early restoration of blood flow and consequently the supply of oxygen and nutrients, cell damage remains irreversible and results in cell death. This article will explain the mechanisms by which ischaemia causes cellular damage, the phenomenon of reperfusion injury and what treatment options are available.


Reperfusion injury is defined as myocardial, vascular or electrophysiological dysfunction caused by restoring blood flow to a previously ischemic tissue [1].

Mechanisms of Ischaemic Myocardial Injury

Myocardial reperfusion injury was first reported in 1960 by Jennings et al. It has been shown that only those ischaemic cardiomyocytes able to recover their ionic homeostasis will survive. However, a variable number of ischaemic cardiomyocytes fail to recover the ionic balance, thus triggering cell death [2]. Interruption of myocardial blood flow causes a series of events that lead to alterations in the myocyte's physiology and architecture including mitochondrial and sarcolemma injury and alterations in intracellular calcium handling, culminating in injury and cell death [3]. Those processes include the decrease of intracellular ATP levels, the change in energy usage from aerobic to anaerobic metabolism and a reduction in intracellular pH.

Initially, this damage is reversible and the restoration of blood flow during this period could recover the normal structure and function of the cells. But if the ischaemia persists for a long period of time, the damage becomes irreversible. During this period of time the ischaemic myocytes are viable, but paradoxically, the restoration of blood flow and the reintroduction of oxygen and energy into an abnormal cellular environment will lead to additional cells' injury and death. The factors contributing to reperfusion injury include damage to cellular membranes and organelles, free-radical formation, leukocyte aggregation, increased mediators of inflammation, platelet and complement activation, endothelial damage, activation of the pro-apoptotic signalling cascade and vasoconstriction [4-7].

From a physiological point of view, four types of injury have been described: The first, it's the stunned myocardium, which is the mechanical myocardial dysfunction that persists despite the absence of irreversible damage and despite restoration of coronary blood flow. The second is the no-reflow phenomenon that is the inability to reperfuse a previously ischaemic region. The third, it's the cardiac dysfunction accompanied by arrhythmia. The last type is the lethal reperfusion injury that consists of death of the cardiomyocytes after reperfusion [1].

Factors Contributing to this Phenomenon


Calcium is an essential element for cell function, including the regulation of cell death. Evidence shows that calcium is one of the main elements involved in myocardial reperfusion injury, since the cytosolic increase of this element gives rise to various processes that terminates in cardiomyocyte injury or death [1,7,8]. The intracellular calcium overload was first demonstrated by Zimmerman et al., in 1967 [9]. Ischaemia induces intracellular accumulation of ions of sodium, hydrogen and calcium culminating in tissue acidosis. Reperfusion produces alterations in the ionic fluxes and evidence suggests that rapid normalization of pH after the ischaemic tissue is reperfused leads to an increase in cytotoxicity. Sodium-dependent buffering mechanisms, including pumps Na+/ H+ and Na+/HC[O.sub.3]- are activated leading to the intracellular accumulation of Na+. Consequently, this high concentration of Na+ increases the exchange of Na+ by the sarcoplasmic [Ca.sub.2]+. The increased [Ca.sub.2]+ entry through L-type calcium channels and the decrease in its reuptake by the sarcoplasmic reticulum promotes the overload of this ion in the myocardial cell. This ionic disbalance results in myocardial stunning, myofibrillar hypercontractility, mitochondrial ultrastructural damage and ATP depletion [10].

Oxygen and Free Radicals

Cardiomyocytes are cells with high energy requirements, which is why they have a high density of mitochondria. It is not strange that these organelles loaded with reactive-oxygen species and proapoptotic materials are directly related to myocardial reperfusion injury. The mitochondrial inner membrane, which is responsible for the potential of the membrane, in normal conditions is impermeable to ions and proteins. The alteration of the inner membrane potential is the process called 'transitional permeability', a process that is believed to be performed by the mitochondrial permeability transition pore (mPTP). mPTP formation creates a non-selective channel between the inner mitochondrial membrane and the sarcoplasm.

The result is an electrochemical gradient where the mitochondrial matrix elements are released into the sarcoplasm. This triggers the biochemical phenomena experienced in reperfusion injury such as oxidative stress, [Ca.sub.2]+ overload and rapid normalization of pH [10]. This is why there has been so much interest in the mPTP as a therapeutic target. It also explains the generation of free radicals through the incomplete reduction of oxygen during the reperfusion injury. Although the cardiomyocytes express endogenous enzymes for scavenging free radicals such as superoxide dismutase, catalase and glutathione peroxidase, its capacity is exceeded after ischaemia and reperfusion.

It has been demonstrated that exogenous free radical entrance also increases the [Ca.sub.2]+ ion load in the cell thereby causing more damage. The leukocytes reaching the site of the injury are also a source of free radicals. Free radicals cause lipid peroxidation leading to rupture of the cell membrane, resulting in cellular oedema and necrosis, denatur ation of proteins including ion channels and enzymes, and rupture of the DNA strands, playing an important role as mediators of cell apoptosis [11].

Platelet Activating Factor (PAF)

PAF is a phospholipid with diverse and potent physiological effects. Under normal physiological conditions, PAF is minimally expressed. Its expression has been reported in various cells including cardiomyocytes. In myocardial reperfusion injury, in addition to its inflammatory role, PAF is believed to be released during oxidative stress mediated by free radicals and there is evidence that this alters the tone of the coronary arteries by inducing prolonged vasoconstriction [12].

Nitric Oxide (NO)

NO is a gas that is synthesized by the enzyme nitric oxide synthase primarily by the endothelial cells, with multiple --mainly vasoactive--actions in the human body. During reperfusion injury, the NO can preserve coronary blood flow, decrease platelet aggregation and reduce the interaction between neutrophils and the endothelium. At low concentrations, NO can improve cardiomyocyte function. In contrast, at high concentrations, NO can depress its function, alter mitochondrial respiratory chain and may even induce apoptosis [13,14].

Cell Apoptosis

Reperfusion induces apoptosis. It requires the activation of caspases, which in turn activate endonucleases responsible for DNA degradation and subsequent cell death. Certain target proteins mark the apoptotic process (In situ end labelling --TUNEL, Annexin V). In essence, viable cells that are reperfused and are provided of oxygen and glucose remain alive. However, reperfusion also provides the energy necessary to complete the apoptotic process and even accelerate it. During reperfusion, it is believed that the failure of ion channels, nitric oxide and some growth factors can trigger apoptosis. Several studies have shown that during myocardial infarction, most of the cardiomyocytes die through apoptosis. However, these studies have been questioned because of their methodology for identifying and measuring apoptosis in infarct tissue. In turn, apoptosis has been a great source of research to reduce the size of the infarct zone [14]. Also, recent work has implicated autophagy in the pathogenesis of ischaemia reperfusion injury. Over time, we will know the real mechanism and implications [15].


During myocardial reperfusion injury, the endothelium and myocardial cells generate inflammatory signals to which neutrophils respond directly. The evi dence shows that neutrophils are directly implicated during the reperfusion injury. Several studies have shown that neutrophils are related to the lethal reperfusion injury type, in which cardiomyocytes that were completely viable die at the end of ischaemia. Neutrophils produce various derivatives that are mediators of reperfusion injury, and produce enzymes such as proteases, gelatinases and collagenases, which damage the extracellular matrix. Neutrophils are a primary source of free radicals. The neutrophils are activated and respond to a large number of mediators.

Some of these mediators are produced in endothelial cells, cardiomyocytes and mast cells. Other mediators are the complement C5a, and various cytokines such as TNFa, IL-1, IL-6, IL-8 and PAF. It is known that the intracoronary infusion of complement C5a stimulate neutrophil adhesion to the vascular endothelium and is associated with decreased blood flow. Arachidonic acid is released in reperfused myocardium by neutrophils and this is a potent neutrophil chemoattractant. The interaction between neutrophils and vascular endothelium is a key step in the inflammatory process, which usually takes place in postcapillary venules. This step is dependent on selectins. In terms of time, during the insult, neutrophil infiltration is a slow process that can begin from 12 hours to 4 days post event. During reperfusion, this time is accelerated and in turn infiltration is increased. The results of all these events are cell necrosis, endothelial damage and microvascular damage [16].

Clinical Manifestations

Reperfusion Arrhythmias

Reperfusion arrhythmias may be mediated by mitochondrial dysfunction and are common among patients treated with thrombolytic therapy, primary percutaneous coronary intervention and cardiac surgery. The most common arrhythmia during reperfusion is accelerated idioventricular rhythm. Ventricular tachycardia and fibrillation can also occur post-thrombolytic therapy, but these arrhythmias are more likely to be seen in persistent vessel's occlusion and infarction. Subsequent to the period of ischaemia, mitochondria may not be able to restore or maintain their internal membrane potential, thereby destabilising the action potential and increasing the susceptibility to the development of arrhythmias [17].

Microvascular Dysfunction

Final recovery of myocardial function requires the preservation of the coronary microvasculature [18]. Microvascular dysfunction, or the phenomenon of "no-reflow" previously mentioned, refers to the insufficient blood flow within the post-ischemic vasculature in rest, and it has been associated with worse cardiovascular outcomes [19]. Platelet activation and activation of complement are associated with microvascular dysfunction, so the aggressive antiplatelet therapy could have beneficial effects in its prevention, including the use of inhibitors of glycoprotein Ilb/lIIa [20-23].

Myocardial Stunning

It's defined as the transient myocardial dysfunction occurring after reperfusion and is believed to be due to persistent anaerobic metabolism even after reperfusion. It has also been associated with microvascular injury [24-26]. Myocardial stunning may recover over time, so inotropic agents can be used for a short time to improve cardiac function and perfusion of organs. Other therapies that may prevent its occurrence are still under investigation.

Myocyte Death

The myocytes' death is the worst consequence of reperfusion injury and data from diverse studies suggest that more than 50% of the size of the infarction can be attributed to this kind of lesion [27,28]. Whereas reperfusion may accelerate or cause further damage to the injury that occurred during the previous ischemia, several studies have focused on the modification of the conditions of reperfusion to evaluate if there is any effect on the extent of damage [29,30].

Treatment of Myocardial Ischaemia-Reperfusion Syndrome

Based on the pathophysiology of reperfusion injury, several possible therapeutic strategies could be considered. However, only few interventions have proved useful in clinical practice, which could be explained by the multiple mechanisms related to myocardial infarction and reperfusion injury. Besides, some mechanisms may play a dual role, as mediators of injury as in the healing process. Targeted therapies against these mechanisms can be unpredictable [16]. Other conditions that may be associated with this potential therapeutic failure include the time of initiation of therapy (some agents might work better if patients are being treated with them previously) and the presence of comorbidities such as diabetes and hypercholesterolaemia. The following are some of the strategies that have been studied with this purpose:

Inhibitors of Glycoprotein IIb/IIIa

Platelet activation plays a role in the myocardial microvascular and reperfusion injuries. GP IIb/IIIa inhibitors are potent inhibitors of platelet activity, but there is not enough evidence for routine use in the management of patients with myocardial ischaemia--reperfusion syndrome [22,23].


It's a substrate for ATP reestablishment, induces vasodilation and inhibits platelet and neutrophils function. Adenosine has been evaluated in different trials, with variable results. Acute Myocardial Infarction Study of Adenosine (AMISTAD) was the first large-scale clinical trial testing adenosine as an adjunct to reperfusion therapy. This trial showed that adenosine infusion (70 pg/kg/min) was efficacious with regard to reducing infarct size in patients with anterior AMI without causing serious adverse clinical events (33% relative reduction in infarct size) [31].

AMISTAD II was designed to examine the effect of adenosine as an adjunct therapy for patients with acute anterior STEMI undergoing either thrombolysis or PCI. In this trial, 2.118 patients were randomized to receive a 3-h intravenous infusion of low-dose adenosine (50 pg/ kg/min), high-dose adenosine (70 pg/kg/ min), or placebo before PCI or within 15 min of the initiation of fibrinolysis. Although the high-dose adenosine group showed a significant reduction in infarct size compared with the control group, no difference in the primary clinical composite endpoint of death, new-onset congestive heart failure, or rehospitalization for congestive heart failure within 6 months was observed [32]. Intracoronary administration of adenosine and a syn thetic agonist of adenosine have been studied in smaller clinical trials, with promising result, but further studies are needed [33,34].


Papaverine has proven useful in improving TIMI flow of the epicardial arteries, but its use has been limited by its association with the occurrence of ventricular arrhythmias, primarily with intracoronary administration [35]. Inhibitors of angiotensin converting enzyme (ACE) can have several beneficial actions on reperfusion, including free-radical scavenging, coronary vasodilation and elevation of bradykinin and prostacyclins levels [36]. In animal models, ACE inhibitors increased coronary blood flow, but have failed to produce improvement in regional ventricular function [37]. Several studies have investigated the effects of inhibiting the synthesis of endothelin-1 or its receptor blockade. Although the results are conflicting, larger studies are ongoing with these drugs [38-41].

Modulation of Ion Channels

Considering that changes in intra- and extra-cellular ion concentrations play a role in some of the processes involved with reperfusion injury, ion channels constitute an attractive therapeutic target for the management of this type of injury. Sodium/hydrogen ion exchange (NHE) is an important regulator of intracellular pH and calcium concentration. Blocking this exchange could reduce calcium uptake and preserve cellular architecture. Experimental studies have demonstrated marked limitation of infarct size when NHE-inhibitors are administered prior to ischaemia [42-45]. However, in two randomized studies the sodium/hydrogen exchange inhibitor eniporide had no impact in terms of reduction in infarct size or clinical outcomes [46,47]. The efficacy of NHE inhibitors administered just prior to reperfusion remains controversial.

Ischaemia of myocardium is associated with increases in the late sodium current ([I.sub.Na]), intracellular sodium and calcium concentrations, calcium overload, and impairment of contractile relaxation. Ranolazine reduces the late [I.sub.Na] and, is expected to decrease sodium entry into ischaemic myocardial cells. As a consequence, ranolazine is proposed to reduce calcium uptake indirectly via the sodium/ calcium exchanger and to preserve ionic homeostasis and reverse ischaemia-reperfusion induced contractile dysfunction. It is effective in the treatment of chronic angina and may be effective in reperfusion injury and in limiting infarct size in AMI patients [48-50]. Finally, within this group, it is important to mention the ATP-sensitive potassium (K-ATP) channel activators. These channels play a role in ischaemic preconditioning and microvascular vasodilation. In small studies, the activator of K-ATP channel nicorandil, was associated with better perfusion and left ventricular wall motion and reduction of adverse events [51,52]. Furthermore, magnetic resonance imaging suggests that the use of nicorandil may improve microvascular obstruction [53]. None of these trials showed satisfactory proof of infarct size reduction in adequately sized trials. Consequently this agent is not currently being used in AMI, and awaits evaluation in larger trials.

GIK Solution

The concept of glucose-insulin-K+-therapy (GIK) was introduced by Sodi-Pallares and thought to be protective by stabilization of the membrane [54]. Combination therapy of glucoseinsulin-potassium has been evaluated as a potential way to stimulate anaerobic glycolysis, increase ATP levels and decrease the release of free fatty acids. Large and well-designed studies including the CREATE-ECLA and DIGAMI 2 studies did not support its use in clinical practice. In the CREATE-ECLA trial (n=20,000; reperfusion therapy in 83%), GIK treatment failed to improve 30-days clinical outcome although there was a trend towards improved clinical outcome in patients undergoing reperfusion therapy by PCI (9% of all patients) [55].

Anti-Neutrophilic andAnti-complement Therapy

Inhibition of accumulation and activation of neutrophil has been associated with controversial results, and has been correlated with decreased infarct size in some studies but not in others [5658]. Unfortunately, the observed delay between the onset of AMI and the administration of anti-neutrophilic therapy (anti-CD-18) may have been related to the decrease in the ability of these agents in mitigating neutrophil-mediated cell injury [56]. Similarly, the results reported with the complement inhibitor pexelizumab were disappointing. This can be explained by the complexity and the multiple steps involved in immune activation reperfusion injury [59-61]. Moreover leukocyte inhibition may have negative effects on the healing process associated with AMI as previously mentioned.

Antioxidant Therapy

The prominent role of oxygen freeradicals in the pathophysiology of reperfusion injury has stimulated several studies to assess the effectiveness of antioxidants in reducing the damages associated [62-70]. The results have been contradictory. Currently, investigation with different molecules (erythropoietin, oestrogens, heme-oxygenase 1, hypoxiainducible factor 1) is ongoing.


The role of magnesium to minimise reperfusion injury was evaluated for the first time in the ISIS-4 (Fourth International Study of Infarct Survival) study, but no benefit was demonstrated. Controversy persisted about the moment of initiation of magnesium infusion, so the MAGIC study was conducted, which showed that magnesium infusion has no effect on mortality even when administered at the time of reperfusion [71,72].


In addition to its immunosuppressive capabilities, the administration of cyclosporine at the time of percutaneous coronary intervention has been found to reduce in infarct size. Calcium overload and excessive production of reactive oxygen species in the first few minutes after reperfusion set off a cascade of biochemical changes that result in the opening of the mitochondrial permeability transition pore (MPTP) in the cardiac cells. The opening of the MPTP leads to mitochondrial dysfunction. The cessation of energy production results in cellular death. Protecting mitochondria is a viable cardioprotective strategy. A pilot study of 58 patients showed that a single dose of cyclosporine administered prior to primary angioplasty in patients with AMI resulted in reduction of the 20% reduction in infarct size assessed by MRI [73,74].

Ischaemic Post-Conditioning

Postconditioning, defined as brief intermittent cycles of ischemia alternating with reperfusion applied after the ischemic event, has been shown to limits infarct size, reducing the number of necrotic, apoptotic and autophagic cells [75-77]. When applied to patients with ST-segment elevation myocardial infarction, the technique includes interventional angioplasty with an inflated balloon for a short period of time and at low pressure, temporarily occluding the infarct-related artery after it achieved an adequate permeability. In a study evaluating the potential of post-ischaemic conditioning after 20 min of sustained ischaemia, post-ischaemic conditioning improved endothelial function. No protection was observed if the applied protocol lasted for more than a minute, suggesting that this strategy should be applied during the first minute of full reflow [78,79]. Some studies evaluating patients with ST-segment elevation myocardial infarction taken to successful percutaneous coronary intervention submitted to ischemic post-conditioning protocols showed that these ones had higher attenuation of ST-segment elevation and improvement in the degree of distal coronary perfusion [80]. Mechanical postconditioning reduces infarct size in patients with ST-segmentelevation myocardial infarction treated with PCI. The impact of mechanical postconditioning seems to be indepen dent of the size of myocardium at risk. More studies are needed with a large number of patients to determine the optimal protocol, to assess treatment efficacy using more accepted measurements of infarct size post-reperfusion and to determine long-term prognosis [81].

Endovascular Cooling

Since myocardial metabolism decreases at lower temperatures, endovascular cooling could achieve some degree of cardioprotection. Endovascular coils and external cooling blankets to achieve temperatures below 33[grados]C during PCI for AMI have been used with this purpose. The COOL-MI study and the ICE-IT study, showed no effect on infarct size in the total population. However, in patients with anterior myocardial infarction cooled to <35[grados]C at the time of reperfusion, infarct sizes were roughly halved [82-84].


Currently, the treatment for AMI is early reperfusion; however, this itself may contribute to the final myocardial infarct size, condition known as reperfusion injury. Reperfusion injury contributes to up to 50% of the total myocardial damage. Despite of many successful results in animals, the translation into the clinical setting has been disappointing for many years. Over the last few decades, the discovery of the phenomena of ischemic preconditioning and postconditioning, along with significant advances in our understanding of the cardioprotective pathways underlying these phenomena, have provided the possibility of successful mechanical and pharmacological interventions against reperfusion injury. Further investigation is required into this field.


[1.] Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med. 2007; 357:1121-35.

[2.] Ruiz M, Garcia D. Fisiopatologia del dano miocardico por isquemia-reperfusion: nuevas oportunidades terapeuticas en el infarto agudo de miocardio. Rev Esp Cardiol. 2009; 62(2):199-209.

[3.] Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation. 1990; 82:II2-II12.

[4.] Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006; 290:H692-H699.

[5.] Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002; 105: 656-62.

[6.] Bialik S, Cryns VL, Drincic A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res. 1999; 85:403-14.

[7.] Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation. 1997; 95:320-23.

[8.] Talukder MA, Zweier JL, Periasamy M. Targeting calcium transport in isch aemic heart disease. Cardiovasc Res. 2009; 84:345-52.

[9.] Zimmerman ANE, Daems W, Hulsmann WC, et al. Morphological changes of heart muscle caused by successive perfusion with calcium-free and calciumcontaining solutions (calcium paradox). Cardiovasc Res. 1967; 1:201-9.

[10.] Turer A, Hill J. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol. 2010; 106(3):360-68.

[11.] Zweier, J, Talukder, M. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006; 70:181-90.

[12.] Penna C, Bassino E, Alloatti G. Platelet activating factor: the good and the bad in the ischemic/reperfused heart. Exp Biol Med. 2011; 236:390-401.

[13.] Schulza R, Kelmb M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004; 61:402-13.

[14.] Eefting F, Rensing B, Wigman J, et al. Role of apoptosis in reperfusion injury. Cardiovascular Research. 2004; 61:41426.

[15.] Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T, Levine B, Sadoshima J. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007; 100:914-22.

[16.] Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004; 61:481-97.

[17.] Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest. 2005; 115:3527-35.

[18.] Iliceto S, Galiuto L, Marchese A, et al. Analysis of microvascular integrity, con tractile reserve, and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography. Am J Cardiol. 1996; 77:441-5.

[19.] Hoffmann R, Haager P, Lepper W, et al. Relation of coronary flow pattern to myocardial blush grade in patients with first acute myocardial infarction. Heart. 2003; 89:1147-51.

[20.] Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344: 1895-903.

[21.] Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998; 98:2695-701.

[22.] de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in STelevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000; 101: 239-43.

[23.] Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003; 42:1879-85.

[24.] Iliceto S, Galiuto L, Marchese A, et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J. 1997; 18:618-24.

[25.] Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996; 93:223-28.

[26.] Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med. 1992; 327:1825-31.

[27.] Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation. 1998; 97:795804.

[28.] Arai M, Lefer DJ, So T, et al. An antiCD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol. 1996; 27:1278-85.

[29.] Hearse DJ. Ischemia, reperfusion, and the determinants of tissue injury. Cardiovasc Drugs Ther. 1990; Suppl 4:767-76.

[30.] Ferrari R, Hearse DJ. Reperfusion Injury: Does It Exist and Does It Have Clinical Relevance? J Thromb Thrombolysis. 1997; 4:25-34.

[31.] Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction Study of Adenosine (AMISTAD) trial. J Am Coll Cardiol. 1999; 34:1711-20.

[32.] Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J. 2006; 27:2400-5.

[33.] Marzilli M, Orsini E, Marraccini P, Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 2000; 101:2154-9.

[34.] Kopecky SL, Aviles RJ, Bell MR, et al. A randomized, double-blinded, placebocontrolled, dose-ranging study measur ing the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study. Am Heart J. 2003; 146:146-52.

[35.] Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J. 1996; 132:959-63.

[36.] Van Gilst, WH, Kingma, JH. Protection of the myocardium against postischemic reperfusion damage: possible role of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992; 19:S13-9.

[37.] Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation. 1996; 93:544-51.

[38.] Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res. 1995; 29:805-12.

[39.] Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993; 27:1613-18.

[40.] Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res. 1997; 33: 518-26.

[41.] Galiuto L, DeMaria AN, del Balzo, U, et al. Endothelin A-antagonist reduces no-reflow and infarct size in dogs. J Am Coll Cardiol. 1999; Special Issue (Suppl):382A.

[42.] Klein HH, Pich S, Bohle RM, et al. Myocardial protection by Na(+)-H+ exchange inhibition in ischemic, reperfused porcine hearts. Circulation. 1995; 92:912-7.

[43.] Meng HP, Maddaford TG, Pierce GN. Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function. Am J Physiol. 1993; 264:H1831-5.

[44.] Hendrikx M, Mubagwa K, Verdonck F, et al. New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart. Circulation. 1994; 89:2787-98.

[45.] Rohmann S, Weygandt H, Minck KO. Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res. 1995; 30:945-51.

[46.] Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail. 2001; 3:747-50.

[47.] Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol. 2001; 38:1644-50.

[48.] Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110:904-10.

[49.] Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart. 2006; 92 Suppl 4:iv6-14.

[50.] Hale, SL, Leeka, JA, Kloner, RA. Improved Left Ventricular Function and Reduced Necrosis after Myocardial Ischemia/Reperfusion in Rabbits Treated with Ranolazine, an Inhibitor of the Late Sodium Channel. J Pharmacol Exp Ther. 2006; 318:418-23.

[51.] Sakata Y, Kodama K, Ishikura F, et al. Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J. 1997; 61:455-8.

[52.] Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol. 1999; 33:654-60.

[53.] Krombach GA, Higgins CB, Chujo M, Saeed M. Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy. Radiology. 2005; 236:510-8.

[54.] Sodi-Pallares D, Testelli MR, Fishleder BL, et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report. Am J Cardiol. 1962; 9:166-81.

[55.] Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE ECLA trial. JAMA. 2005; 293: 437-46.

[56.] Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation. 2001; 104:2778-83.

[57.] Gonon AT, Gourine AV, Middelveld RJ, et al. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol. 2001; 96:454-62.

[58.] Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med. 2002; 30:S214-9.

[59.] Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation. 2003; 108:1176-83.

[60.] Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003; 108:1184-90.

[61.] Armstrong PW, Granger CB, et al. APEX AMI Investigators. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA. 2007; 297:43-51.

[62.] Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005; 45:1406-12.

[63.] Hanlon PR, Fu P, Wright GL, et al. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 2005; 19:1323-25.

[64.] Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol. 2005; 100:397403.

[65.] Xu B, Dong GH, Liu H, et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci. 2005; 35: 161-8.

[66.] Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther. 2005; 19:33-40.

[67.] Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause. 2006; 13:80-6.

[68.] Sbarouni E, Iliodromitis EK, Bofilis E, et al. Estrogen alone or combined with edroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol. 2003; 467:163-8.

[69.] Liu X, Pachori AS, Ward CA, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J. 2006; 20:207-16.

[70.] Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res. 2000; 86:319-25.

[71.] ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous mag nesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995; 345:669-82.

[72.] Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomized controlled trial. Lancet. 2002; 360:1189-96.

[73.] Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res. 2003; 60:617-25.

[74.] Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008; 359: 473-81.

[75.] Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003; 285:H57988.

[76.] Argaud L, Gateau-Roesch O, Raisky O, et al. Postconditioning inhibits mitochondrial permeability transition. Circulation. 2005; 111: 194-7.

[77.] Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res. 2006; 70:200-11.

[78.] Loukogeorgakis SP, Panagiotidou AT, Yellon DM, et al. Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation. 2006; 113:1015-9.

[79.] Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol. 2005; 289:H2-7.

[80.] Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv. 2005; 65:361-7.

[81.] Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation. 2005; 112:2085-88.

[82.] Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol. 2002; 40:1928-34.

[83.] Ly HQ, Denault A, Dupuis J, et al. A pilot study: the Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J. 2005; 150:933.

[84.] Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol. 2004; 93:636-39.


Jairo Alejandro Aldana Bitar

David Santacruz Pacheco


(1) Medical Student, Pontificia Universidad Javeriana, Bogota, Colombia.

(2) Internist, Cardiology's fellowship, Pontificia Universidad Javeriana, Bogota, Colombia.

(3) Internist, Cardiologist, Interventional cardiologist. Professor of Internal Medicine and Cardiology, Pontificia Universidad Javeriana, Bogota, Colombia

Received: 09/02/2014

Reviewed: 18/02/2014:

Accepted: 04/03/2014
COPYRIGHT 2014 Pontificia Universidad Javeriana
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Aldana Bitar, Jairo Alejandro; Santacruz Pacheco, David; Urina Triana, Manuel Eliseo
Publication:Revista Universitas Medica
Date:Apr 1, 2014
Previous Article:Diagnostico diferencial en lesiones congenitas de la pared toracoabdominal fetal y neonatal.
Next Article:Asociacion de las alteraciones del sueno con el deficit de atencion e hiperactividad en pediatria.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters